165 related articles for article (PubMed ID: 35238476)
1. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
Safadi R; Rahimi RS; Thabut D; Bajaj JS; Ram Bhamidimarri K; Pyrsopoulos N; Potthoff A; Bukofzer S; Wang L; Jamil K; Devarakonda KR
Clin Transl Sci; 2022 Jun; 15(6):1449-1459. PubMed ID: 35238476
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Rahimi RS; Safadi R; Thabut D; Bhamidimarri KR; Pyrsopoulos N; Potthoff A; Bukofzer S; Bajaj JS
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2626-2635.e7. PubMed ID: 33069881
[TBL] [Abstract][Full Text] [Related]
3. Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Wang X; Tseng J; Mak C; Poola N; Vilchez RA
Clin Pharmacokinet; 2021 Dec; 60(12):1557-1567. PubMed ID: 34125423
[TBL] [Abstract][Full Text] [Related]
4. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
Jalan R; Wright G; Davies NA; Hodges SJ
Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
[TBL] [Abstract][Full Text] [Related]
5. Ornithine phenylacetate revisited.
Jover-Cobos M; Noiret L; Sharifi Y; Jalan R
Metab Brain Dis; 2013 Jun; 28(2):327-31. PubMed ID: 23456516
[TBL] [Abstract][Full Text] [Related]
6. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.
Jover-Cobos M; Noiret L; Lee K; Sharma V; Habtesion A; Romero-Gomez M; Davies N; Jalan R
J Hepatol; 2014 Mar; 60(3):545-53. PubMed ID: 24512823
[TBL] [Abstract][Full Text] [Related]
7. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
Oria M; Romero-Giménez J; Arranz JA; Riudor E; Raguer N; Córdoba J
J Hepatol; 2012 Jan; 56(1):109-14. PubMed ID: 21835138
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
9. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
Davies NA; Wright G; Ytrebø LM; Stadlbauer V; Fuskevåg OM; Zwingmann C; Davies DC; Habtesion A; Hodges SJ; Jalan R
Hepatology; 2009 Jul; 50(1):155-64. PubMed ID: 19437490
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
Wang X; Vilchez RA
Clin Pharmacokinet; 2022 Apr; 61(4):515-526. PubMed ID: 34786649
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
Stravitz RT; Gottfried M; Durkalski V; Fontana RJ; Hanje AJ; Koch D; Hameed B; Ganger D; Subramanian RM; Bukofzer S; Ravis WR; Clasen K; Sherker A; Little L; Lee WM;
Hepatology; 2018 Mar; 67(3):1003-1013. PubMed ID: 29080224
[TBL] [Abstract][Full Text] [Related]
12. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Ventura-Cots M; Arranz JA; Simón-Talero M; Torrens M; Blanco A; Riudor E; Fuentes I; Suñé P; Soriano G; Córdoba J
J Clin Gastroenterol; 2013; 47(10):881-7. PubMed ID: 23751856
[TBL] [Abstract][Full Text] [Related]
13. Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia.
Dadsetan S; Sørensen M; Bak LK; Vilstrup H; Ott P; Schousboe A; Jalan R; Keiding S; Waagepetersen HS
Biochem Pharmacol; 2013 Jan; 85(1):115-23. PubMed ID: 23103564
[TBL] [Abstract][Full Text] [Related]
14. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
[TBL] [Abstract][Full Text] [Related]
15. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
Kristiansen RG
Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
[TBL] [Abstract][Full Text] [Related]
16. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.
Ventura-Cots M; Concepción M; Arranz JA; Simón-Talero M; Torrens M; Blanco-Grau A; Fuentes I; Suñé P; Alvarado-Tapias E; Gely C; Roman E; Mínguez B; Soriano G; Genescà J; Córdoba J
Therap Adv Gastroenterol; 2016 Nov; 9(6):823-835. PubMed ID: 27803737
[TBL] [Abstract][Full Text] [Related]
17. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
Kristiansen RG; Rose CF; Ytrebø LM
Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
[TBL] [Abstract][Full Text] [Related]
18. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.
Ytrebø LM; Kristiansen RG; Maehre H; Fuskevåg OM; Kalstad T; Revhaug A; Cobos MJ; Jalan R; Rose CF
Hepatology; 2009 Jul; 50(1):165-74. PubMed ID: 19554542
[TBL] [Abstract][Full Text] [Related]
19. Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats.
Balasubramaniyan V; Wright G; Sharma V; Davies NA; Sharifi Y; Habtesion A; Mookerjee RP; Jalan R
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G145-52. PubMed ID: 21903766
[TBL] [Abstract][Full Text] [Related]
20. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM
Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
